Document Detail


One-year results of bevacizumab intravitreal and posterior sub-Tenon injection of triamcinolone acetonide with reduced laser fluence photodynamic therapy for retinal angiomatous proliferation.
MedLine Citation:
PMID:  22990616     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: Our aim was to study the efficacy of combined triple therapy with intravitreal bevacizumab injections (IVB), posterior sub-Tenon injection of triamcinolone acetonide (STTA), and reduced laser fluence photodynamic therapy (RFPDT) in Japanese patients with retinal angiomatous proliferation (RAP).
DESIGN: This was a retrospective, observational, consecutive case series.
METHODS: Fifteen consecutive RAP treatment-naïve eyes were treated with triple therapy of IVB, STTA, and RFPDT (25 J/cm(2) of laser fluence). Whenever there was a recurrence of retinal-retinal anastomosis (RRA) or retinal-choroidal anastomosis (RCA) and marked leakage from subretinal neovascularization, the triple therapy was reapplied. When there were only intraretinal exudative and/or hemorrhagic changes without distinct RRA or RCA, IVB alone was applied.
RESULTS: The mean logarithm of the minimum angle of resolution (logMAR) best-corrected visual acuity (BCVA) at baseline improved significantly (from 0.489 to 0.294 12 months) (paired t test, p = 0.043). LogMAR BCVA at 12 months was stable or improved by ≥ 0.2 in 14 eyes (93.3 %). Mean number of triple therapy instituted during the 12-month study period was 1.2, and mean number of IVB treatments was 1.4.
CONCLUSION: Combined IVB, STTA, and RFPDT for RAP was effective in maintaining or improving VA at 1 year. In addition, the number of treatments could be markedly reduced.
Authors:
Yukari Shirakata; Chieko Shiragami; Ayana Yamashita; Eri Nitta; Atsushi Fujiwara; Fumio Shiraga
Related Documents :
23609996 - Long-term outcome of vincristine-aspirin-ticlopidine (vat) therapy for vascular tumors ...
24572676 - Long-term, drug-free remission of sympathetic ophthalmia with high-dose, short-term chl...
11271286 - Comparison of uw versus htk solution for myocardial protection in heart transplantation.
24131066 - A patient with cupping-related post-inflammatory hyperpigmentation successfully treated...
3532186 - Postappendectomy fluid collections in children: incidence, nature, and evolution evalua...
19893716 - Clinical and radiological outcomes of anterior cervical interbody fusion using hydroxya...
Publication Detail:
Type:  Case Reports; Journal Article     Date:  2012-09-19
Journal Detail:
Title:  Japanese journal of ophthalmology     Volume:  56     ISSN:  1613-2246     ISO Abbreviation:  Jpn. J. Ophthalmol.     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-11-15     Completed Date:  2013-02-01     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  0044652     Medline TA:  Jpn J Ophthalmol     Country:  Japan    
Other Details:
Languages:  eng     Pagination:  599-607     Citation Subset:  IM    
Affiliation:
Department of Ophthalmology, Kagawa University Faculty of Medicine, 1750-1 Ikenobe Miki-cho, Kagawa 761-0793, Japan. y-shira@med.kagawa-u.ac.jp
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Aged, 80 and over
Angiogenesis Inhibitors / administration & dosage*
Antibodies, Monoclonal, Humanized / administration & dosage*
Coloring Agents / diagnostic use
Combined Modality Therapy
Female
Fluorescein Angiography
Glucocorticoids / administration & dosage*
Humans
Indocyanine Green / diagnostic use
Injections
Intravitreal Injections
Male
Photochemotherapy*
Recurrence
Retinal Neovascularization / drug therapy*,  physiopathology
Retreatment
Retrospective Studies
Tenon Capsule / drug effects
Tomography, Optical Coherence
Treatment Outcome
Triamcinolone Acetonide / administration & dosage*
Vascular Endothelial Growth Factor A / antagonists & inhibitors
Visual Acuity / physiology
Wet Macular Degeneration / drug therapy*,  physiopathology
Chemical
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Antibodies, Monoclonal, Humanized; 0/Coloring Agents; 0/Glucocorticoids; 0/VEGFA protein, human; 0/Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V/bevacizumab; 3599-32-4/Indocyanine Green; 76-25-5/Triamcinolone Acetonide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Side Effects of Long-term Glutamine Supplementation.
Next Document:  Scaffolds for bone tissue engineering fabricated from two different materials by the rapid prototypi...